An educational live and enduring activity provided by i3 Health has demonstrated increased expertise and learning outcomes for treatment of patients with prostate cancer.
Prostate cancer is the most common cancer in American men, seeing an average of 1 out of 8 men being diagnosed with it within their lifetime. The typical treatment for progressive prostate disease is androgen deprivation therapy (ADT); however, it is common for prostate cancer to become castration-resistant or resistant to ADT. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease with a lack of effective treatment options. It is estimated in the United States that there will be 268,490 new cases of prostate cancer this year, with 34,500 resulting in death.
To address the knowledge gaps regarding the treatment of individuals with prostate cancer, i3 Health provided a continuing medical education (CME)–approved virtual ancillary and enduring educational activity, Clinical Updates and Expert Guidance in Prostate Cancer, led by Judd W. Moul, MD, Professor of Urologic Surgery at Duke University School of Medicine. The activity received commercial support from Sanofi.
Between the live virtual ancillary and enduring activities, a total of 456 learners participated, and 304 completed the activity for credit. The live activity was presented on May 29, 2020, at the American Society of Clinical Oncology (ASCO) 2020 Virtual Conference. To extend this activity and promote educational gains, an enduring activity was made available via i3Health.com, from June 3, 2020, to June 2, 2021. Most learners who participated in the live activity were physicians (40%) and pharmacists (20%), followed by registered nurses and nurse practitioners (1.5%), and those who chose "other" as their profession (37%). For the online enduring activity, the majority of participants were registered nurses (87%), followed by physicians (8%), nurse practitioners (2%), pharmacists and nurse practitioners (1% each), and those who chose "other" as their profession (3%). Attendees from both the live and enduring activity had been in their practice for an average of 17 years and saw an average of 19 patients with prostate cancer per month.
To evaluate knowledge gained in this activity, participants were presented with an identical pretest and posttest before and after the activity. The baseline data collected demonstrated a significant shortcoming in knowledge of treatment of patients with prostate cancer, including competence when evaluating recent efficacy and safety data on novel therapeutic strategies for patients with castration-sensitive/resistant nonmetastatic prostate cancer and in assessing recent study findings on novel combination and sequential treatment strategies for prostate cancer, as well as their implications for current practice.
Prior to the start of the activity, the pretest revealed that only 24% of learners were able to identify ADT/radiotherapy plus enzalutamide as the appropriate treatment for a patient with low-volume metastatic hormone-sensitive prostate cancer (HSPC); 27% successfully identified darolutamide as the best option to treat a patient with high-risk CRPC and a history of falls; 45% successfully identified cabazitaxel/prednisone as the appropriate option to treat a patient with metastatic CRPC who was previously treated with docetaxel and has a rapidly rising prostate-specific antigen (PSA); 27% identified that the combination of radium-223 with abiraterone/prednisone would not prolong a patient's expected survival with high-risk CRPC and bone metastases; and 45% understood that enzalutamide would not be superior to olaparib for prolonging a patient's progression-free survival with BRCA1-mutated metastatic CRPC.
Each topic saw a significant increase in learners' knowledge and proficiency during the activity, as revealed by the posttest data: 65% more learners were successful in identifying the efficacy of ADT/radiotherapy plus enzalutamide; 63% more learners were successful in identifying the efficacy and safety of darolutamide; 38% more learners understood the efficacy of cabazitaxel/prednisone; 69% more learners gained competence in the efficacy and safety of radium-223; and 51% more learners gained competence in the efficacy of olaparib.
Upon completion of the activity, 83% of learners reported that they felt more confident in treating their patients with prostate cancer, and 84% felt that the material provided would be useful to improve the outcomes of their patients.
The data revealed by the posttest assessment affirm the effectiveness of the educational content and show significant gains in knowledge and proficiency regarding strategies for the optimization and treatment of patients with prostate cancer. i3 Health has determined that the multidisciplinary team may benefit from CME/NCPD activities that provide education on novel therapeutic agents, novel combination and sequential treatment strategies, and safety of novel therapies for prostate cancer.
i3 Health (2021). Clinical Updates and Expert Guidance in Prostate Cancer: activity outcomes report. Data on file.